companiesCompany
Curesponse
Israeli company whose cResponse test keeps a patient's tumour fragment alive, with its vessels and immune cells, to test which treatments it responds to.
Ex vivo tumour-fragment culture combined with rapid genomics; a 2026 clinical-utility study showed the assay can rule out ineffective regimens and reclassify predicted non-responders. Distributed in the UK through EDX Medical. Founded by Seth Salpeter, Guy Neev, Ravid Straussman, and Nancy Gavert.